Sintx Technologies (SINT) Company Report

SINTX Technologies has entered into a supply agreement with Evonik Corporation to manufacture its proprietary silicon nitride-PEEK (SiN/PEEK) composite.
This agreement facilitates the immediate production of patient-specific, AI-designed, 3D-printed implants at SINTX's U.S. facilities.
The SiN/PEEK composite is designed for critical applications, including humanitarian vertebral body replacement (VBR) implants for oncology patients, offering benefits such as antipatogenic surface behavior and osteogenic support.
The partnership aims to ensure consistent quality, reliable supply, and scalability for the high-performance SiN/PEEK composite, with plans to make it available to other qualified manufacturers.

Dec 1, 2025, 5:16 PM

Press Release

SINTX Technologies Contracts Evonik for SiN/PEEK Composite Supply

SINT

Product Launch

New Projects/Investments

SINTX Technologies has signed a supply agreement with Evonik Corporation for the manufacturing of its proprietary silicon nitride-PEEK (SiN/PEEK) composite.
This agreement enables SINTX to immediately begin manufacturing AI-assisted, 3D-printed, patient-specific implants using the SiN/PEEK composite.
The SiN/PEEK composite is intended for use in human vertebral body replacement (VBR) implants for oncology patients and offers advantages such as antipatogenic surface characteristics, osteogenic potential, and enhanced visualization compared to standard PEEK.
SINTX plans to use the SiN/PEEK composite for regulatory clearances of traditional implantable devices and may make it available to other qualified manufacturers for complex implant indications.

Dec 1, 2025, 5:16 PM

Press Release

SINTX Technologies Signs Supply Agreement with EVONIK

SINT

Product Launch

New Projects/Investments

SINTX Technologies has signed a supply agreement with Evonik Corporation for the production of its proprietary Silicon Nitride-PEEK (SiN/PEEK) composite.
This composite material is designed for AI-supported additive manufacturing of patient-specific implants, enabling SINTX to immediately begin manufacturing these products.
The SiN/PEEK composite offers advantages such as antipathogenic surface properties, osteogenic potential, and improved visualization compared to conventional PEEK.
SINTX is addressing immediate humanitarian requests for vertebral body replacement implants for oncology patients and intends to use the composite to support regulatory approval for other implantable products.

Dec 1, 2025, 5:16 PM

Press Release

SINTX Technologies Signs Supply Agreement with EVONIK

SINT

New Projects/Investments

Product Launch

SINTX Technologies, Inc. (SINT) announced on December 1, 2025, a supply agreement with Evonik Corporation to manufacture SINTX's proprietary silicon nitride–PEEK compound (SiN/PEEK).
This compound is engineered for AI-assisted, 3D-printed patient-specific implants, enabling SINTX to immediately begin manufacturing these devices.
The SiN/PEEK material is expected to offer advantages over standard PEEK, including antipathogenic surface characteristics, osteogenic potential, and improved visualization.
SINTX has already received physician requests for humanitarian-use vertebral body replacement (VBR) implants for orthopedic and neurosurgical oncology patients.

Dec 1, 2025, 1:35 PM

8-K

SINTX Technologies Reports Q3 2025 Financial Results and FDA Clearance

SINT

Earnings

Product Launch

New Projects/Investments

SINTX Technologies, Inc. reported a net loss of $3.5 million and revenue of $0.2 million for Q3 2025, with operating expenses decreasing 51% year-over-year to $3.4 million.
The company achieved FDA 510(k) clearance for its SINAPTIC® Foot & Ankle Osteotomy Wedge System and recorded its first commercial revenue from the orthobiologic product OsseoSculpt™.
SINTX strengthened its liquidity by raising an additional $4.3 million in gross proceeds through warrant inducement and common stock warrant exercises.

Nov 13, 2025, 1:05 PM

8-K

Sintx Technologies Announces Launch of OsseoSculpt™ and Initial Revenue

SINT

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

SINTX Technologies announced the execution of a private label agreement to supply OsseoSculpt™, a new biologic designed to complement its FDA 510(K) cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System.
The company recorded its first commercial revenue from OsseoSculpt™ in Q3 2025 following successful evaluations by multiple design surgeons.
SINTX expects that the utilization of this biologic product will improve the overall economic profile of its wedge portfolio as commercialization scales.
A broader U.S. rollout of OsseoSculpt™ is planned through Q4 2025–Q1 2026, aligned with wedge availability and surgeon training cycles.

Nov 3, 2025, 1:00 PM

Press Release

SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Osteotomy Wedge System

SINT

Product Launch

SINTX Technologies received U.S. FDA 510(k) clearance for its SINAPTIC® Foot & Ankle Osteotomy Wedge System, enabling the company to enter the U.S. foot and ankle reconstruction surgery market.
The company plans to commercially launch the SINAPTIC® system in the U.S. in Q1 2026.
The SINAPTIC® system incorporates SINTX's patented silicon nitride biomaterial, which offers benefits such as osteopromotion, antibacterial properties, hydrophilicity, and enhanced imaging clarity.
SINTX views this as a significant revenue opportunity within the global foot and ankle device market, which was estimated at $4.75 billion to $5.4 billion in 2024.

Oct 20, 2025, 8:14 PM

Press Release

SINTX Technologies' SINAPTIC® Foot & Ankle Implant System Receives FDA Clearance

SINT

Product Launch

New Projects/Investments

SINTX Technologies (NASDAQ: SINT) has received FDA 510(k) clearance for its SINAPTIC® Foot & Ankle Osteotomy Wedge System.
This clearance allows SINTX to enter the U.S. foot and ankle reconstruction market, with commercialization planned for Q1 2026.
The SINAPTIC® system incorporates SINTX's proprietary silicon nitride biomaterial, which is noted for promoting bone regeneration, possessing antibacterial properties, and offering enhanced imaging visibility.
The global foot and ankle device market, which SINTX is entering, was estimated to be between $4.75 billion and $5.4 billion in 2024.

Oct 20, 2025, 8:14 PM

Press Release

SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot and Ankle Implant System

SINT

Product Launch

New Projects/Investments

SINTX Technologies (SINT) announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its SINAPTIC® Foot and Ankle Osteotomy Wedge System.
This clearance allows SINTX to commercially enter the reconstructive foot and ankle surgery market in the United States, with a planned commercial launch in Q1 2026.
The SINAPTIC system combines SINTX's proprietary silicon nitride biomaterial with surgeon-informed implant designs and a single-use sterile instrument kit.
The global foot and ankle device market is estimated to be between $4.75 billion and $5.4 billion in 2024.

Oct 20, 2025, 8:14 PM

Press Release

SINTX Technologies Receives FDA Clearance for Foot and Ankle Implant System

SINT

Product Launch

New Projects/Investments

SINTX Technologies (NASDAQ: SINT) announced FDA 510(k) clearance for its SINAPTIC® Foot & Ankle Osteotomy Wedge System, allowing commercial entry into the US reconstructive foot and ankle surgery market.
The company plans a US market launch in Q1 2026, intending to leverage its US production facilities to boost revenue growth and operational efficiency.
The SINAPTIC system incorporates SINTX's silicon nitride biomaterial, providing benefits such as pro-osteogenic, bacteriostatic, and hydrophilic properties, along with improved imaging visibility.
This approval is considered a crucial commercial milestone, positioning SINTX in the global foot and ankle implant market, which is estimated to reach $4.75 to $5.4 billion in 2024.